Screen Shot 2014-07-28 at 14.00.45

Derek Jennings, a Hep C worker, at a launch to raise awareness about Hepatitis C at Dublin Castle this morning

Rachel Ahearne writes:

“To mark World Hepatitis Day today, Community Response and Janssen have joined forces to launch ‘Treat It, Beat It’ a campaign to raise awareness of hepatitis C and highlight the need for the HSE’s National Hepatitis C Strategy to be resourced as a matter of urgency.

An estimated 20,000 to 50,000 people are infected with hepatitis C in Ireland, with many of those infected undiagnosed and untreated.

“As part of the ‘Treat It, Beat It’ campaign, Community Response and Janssen have developed a facility on the Community Response website for people to petition their local TDs urging them to ensure that resourcing of the National Hepatitis C Strategy is a priority in Budget 2015. Community Response has also urged other voluntary groups to include hepatitis C in their respective pre-budget submissions.

To support the ‘Treat It, Beat It’ campaign and petition your local public representative visit Community Response

For more information visit hepinfo.ie or call the HSE helpline 1800 459 459

Thanks Rachel

Leah Farrell/Photocall Ireland

Screen Shot 2014-07-28 at 13.27.38Screen Shot 2014-07-28 at 13.15.33

Bongobob writes:

Film footage of Palestine in 1896 was recently published online thanks to Lobster Films. It shows Palestinians of all faiths – Christians, Jews and Muslims – living side by side, and praying side by side.

Footage filmed by the Lumière Brothers and extracted from the documentary Palestine: Story of a Land by Simone Bitton.

Screen Shot 2014-07-28 at 12.39.05

 European Ombudsman Emily O’Reilly

The European Ombudsman, Emily O’Reilly, has opened an investigation into whether the EU administration is living up to its obligation to introduce internal whistleblowing rules. She has asked nine EU institutions, including the European Commission, Parliament, and Council, to inform her by 31 October 2014 about the rules they have in place, or intend to introduce.

She explained: “The Commission’s EU Anti-Corruption Report warns that corruption can seriously harm the economy and undermine the trust of citizens in democratic institutions. Whistleblowers play a key role in uncovering serious irregularities. I want to ensure that the EU institutions have in place the necessary rules to protect whistleblowers and to deal with complaints they submit about how they have been treated.”

Ombudsman: What are EU institutions doing to protect whistleblowers? (European Ombudsman)

Previously: Blessed Are The Whistleblowers

The Chilling Effect

Sam Boal/Photocall Ireland

 

90155036Screen Shot 2014-07-28 at 11.27.08

A table (above) showing comparative generic drug prices between Ireland and Britain, from yesterday’s Sunday Business Post

Susan Mitchell, the health correspondent with the Sunday Business Post, spoke to Rachel English on Morning Ireland this morning in relation to the price of generic medicines in Ireland.

Rachel English: “Tell us about some of the price differences between here and the UK because there are some quite staggering differences.”

Susan Mitchell: “Some of them are absolutely colossal, you’re right. We have one which is called, the generic name of this drug is Olanzapine and the original brand would be called Zyprexa which is what a lot of patients would know it as. The British price is €2.65, the Irish price is €71.97, so it’s just absolutely massive.”

English: “It’s €2.65 versus €71.97, that’s just extraordinary…”

Mitchell: “It is extraordinary. Now, to be fair, that was the biggest variation we’ve seen but many of the others were also, were also huge. There was another psychiatric drug called [Anti-depressant] Seroquel, the brand name I’m not even going to attempt to pronounce it but the Irish price is €34.80, in other words what the HSE is paying. The NHS is paying €2.90. And there were many, many other examples for a variety of different medicines, medicines to treat breast cancer, statins, which are used by hundreds of thousands of patients, so these are adding up to an enormous amount of money for the State and the taxpayer.”

English: “For years, we were told that the wider use of generic drugs would be key to bringing down health costs, so why are the prices of these drugs so high?”

Mitchell: “I really cannot answer that. The HSE has brought down the prices. They have. The reference price which they’ve now set for all of these medicines and they’ve set prices for about 20 medicines over the past year is certainly lower than what it was. But the differentials between here and the UK remain absolutely colossal. I don’t know why that is. The HSE says they have to be cognisant of things like security and supply, we’re a smaller market. There is, I know that some people would, you know, theorise that we have to keep big pharma in the country happy because they employ so many people. A lot of other people dispute that because they say that nobody in pharma would expect variations of this magnitude, it’s more to do with incompetence more than anything else. I really can’t explain why the variations are so huge.”

English: “So, what’s being done to tackle this problem?”

Mitchell: “Well reference pricing was suppose to tackle this problem and that’s what’s so disappointing about this – certainly from taxpayers’ perspectives and, indeed, patient groups. Because reference pricing was supposed to bring our prices down and bring us into line with the rest of Europe. And that was what former health minister James Reilly actually said. He said that, under reference pricing, you know the time, or the variations between here and the UK would end. Unfortunately they haven’t.”

English: “Have the pharmaceutical companies had anything to say about this?”

Mitchell: Very little, they’ve said very little. Other than the fact that prices have come down, and indeed they have. They also would say that we’re a much smaller market. And, another important point and I think that is a valid point is that we have had a very, very small number or the competition for generic market here in Ireland has been quite small in the past. So there aren’t as many companies competing for businesses. So that possibly is a factor but as people suggested to me, why don’t we bypass all the generic companies here and go straight to the UK and buy our medicines from them?”

English: “And at the moment, how is the price decided? Who does the deal for the State?”

Mitchell: “The HSE does this. So effectively what happens is the Irish Medicines Board groups a bunch of medicines in the same bracket. So these would all be off-patent and generic medicines. So if you take something like Atorvastatin, the original brand was Lipitor. When that comes off patent, the Irish Medicines Board bunches all of the various different Atorvastatins in a particular group. And the HSE then goes in and sets what is called a reference price. And this reference price is the amount that the HSE will reimburse pharmacists for that medicine. If someone with a medical card wants the original branded product, or a more expensive variation, they must pay the difference themselves, but this is what the HSE is paying.”

English: “You’ve been writing about this for several years now. Do you see that any attempt is being made to try and address the problems?”

Mitchell: “There is an attempt being made but I feel it’s inadequate. I don’t think that anybody can even try to justify variations of this magnitude. I think there’s something seriously wrong. And if the HSE is finding that pharma companies aren’t playing ball, well then it should come out and say this, and say this publicly and arguably maybe look to bypass some of these smaller companies in this market and go direct to the UK and purchase our medicines there.”

Listen back in full here

Pic: Susan Mitchell